Marc S Rendell

List of Publications by Year in Descending Order

Source: https://exaly.com/author-pdf/1043356/marc-s-rendell-publications-by-year.pdf
Version: 2024-04-04

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.
The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

63 papers	2,393 citations	23 h-index	48 g-index
64 ext. papers	2,679 ext. citations	6.4 avg, IF	5.03 L-index

#	Paper	IF	Citations
63	The Importance of Understanding the Stages of COVID-19 in Treatment and Trials. *AIDS Reviews*, **2021**, 23, 40-47	1.5	23
62	The time to offer treatments for COVID-19. *Expert Opinion on Investigational Drugs*, **2021**, 30, 505-518	5.9	9
61	Pharmacotherapeutic options for prediabetes. *Expert Opinion on Pharmacotherapy*, **2021**, 22, 45-54	4	0
60	The time to develop treatments for diabetic neuropathy. *Expert Opinion on Investigational Drugs*, **2021**, 30, 119-130	5.9	1
59	Current and emerging gluconeogenesis inhibitors for the treatment of Type 2 diabetes. *Expert Opinion on Pharmacotherapy*, **2021**, 22, 2167-2179	4	1
58	The journey from gene knockout to clinical medicine: telotristat and sotagliflozin. *Drug Design, Development and Therapy*, **2019**, 13, 817-824	4.4	5
57	Premix insulins in type 1 diabetes: the coming of degludec/aspart. *Expert Opinion on Drug Metabolism and Toxicology*, **2019**, 15, 341-348	5.5	3
56	Commentary: SGLT inhibitors in type 1 diabetes: Place in therapy and a risk mitigation strategy for preventing diabetic ketoacidosis - the STOP DKA protocol. *Diabetes, Obesity and Metabolism*, **2019**, 21, 2189-2191	6.7	1
55	Albiglutide for the management of type 2 diabetes. *Expert Review of Endocrinology and Metabolism*, **2018**, 13, 1-8	4.1	6
54	Efficacy and safety of sotagliflozin in treating diabetes type 1. *Expert Opinion on Pharmacotherapy*, **2018**, 19, 307-315	4	5
53	Sotagliflozin: a combined SGLT1/SGLT2 inhibitor to treat diabetes. *Expert Review of Endocrinology and Metabolism*, **2018**, 13, 333-339	4.1	5
52	Albiglutide for the treatment of type 2 diabetes mellitus: An integrated safety analysis of the HARMONY phase 3 trials. *Diabetes Research and Clinical Practice*, **2017**, 126, 230-239	7.4	16
51	United States experience of insulin degludec alone or in combination for type 1 and type 2 diabetes. *Drug Design, Development and Therapy*, **2017**, 11, 1209-1220	4.4	2
50	Three-year data from 5 HARMONY phase 3 clinical trials of albiglutide in type 2 diabetes mellitus: Long-term efficacy with or without rescue therapy. *Diabetes Research and Clinical Practice*, **2017**, 131, 49-60	7.4	16
49	The safety of albiglutide for the treatment of type 2 diabetes. *Expert Opinion on Drug Safety*, **2017**, 16, 1089-1097	4.1	4
48	Commentary on Almassalha et al., "The Greater Genomic Landscape: The Heterogeneous Evolution of Cancer". *Cancer Research*, **2016**, 76, 5602-5604	10.1	4
47	Screening for familial and hereditary prostate cancer. *International Journal of Cancer*, **2016**, 138, 2579-91	7.5	33

46	Efficacy and safety of once-weekly GLP-1 receptor agonist albiglutide (HARMONY 2): 52 week primary endpoint results from a randomised, placebo-controlled trial in patients with type 2 diabetes mellitus inadequately controlled with diet and exercise. *Diabetologia*, **2016**, 59, 266-74	10.3	64
45	Long-Term Performance of Point-of-Care Hemoglobin A1c Assays. *Journal of Diabetes Science and Technology*, **2016**, 10, 1308-1315	4.1	10
44	Albiglutide: a unique GLP-1 receptor agonist. *Expert Opinion on Biological Therapy*, **2016**, 16, 1557-1569	5.4	11
43	Sotagliflozin, a Dual SGLT1 and SGLT2 Inhibitor, as Adjunct Therapy to Insulin in Type 1 Diabetes. *Diabetes Care*, **2015**, 38, 1181-8	14.6	138
42	DPP-4 inhibitors: focus on safety. *Expert Opinion on Drug Safety*, **2015**, 14, 127-40	4.1	34
41	Glucagon-like polypeptide agonists in type 2 diabetes mellitus: efficacy and tolerability, a balance. *Therapeutic Advances in Endocrinology and Metabolism*, **2015**, 6, 109-34	4.5	33
40	The future of inpatient diabetes management: glucose as the sixth vital sign. *Expert Review of Endocrinology and Metabolism*, **2013**, 8, 195-205	4.1	4
39	The path to approval of new drugs for diabetes. *Expert Opinion on Drug Safety*, **2013**, 12, 195-207	4.1	11
38	A reappraisal of the risks and benefits of treating to target with cholesterol lowering drugs. *Drugs*, **2013**, 73, 1025-54	12.1	18
37	Glargine safety, diabetes and cancer. *Expert Opinion on Drug Safety*, **2013**, 12, 247-63	4.1	11
36	What the U.S. Preventive Services Task Force missed in its prostate cancer screening recommendation. *Annals of Internal Medicine*, **2012**, 157, 137-8	8	54
35	The effect of vasoactive agents on post-pressure hyperemia. *Microvascular Research*, **2012**, 84, 345-50	3.7	2
34	Alogliptin benzoate for the treatment of type 2 diabetes. *Expert Opinion on Pharmacotherapy*, **2012** , 13, 553-63	4	17
33	A 21 CFR Part 11 compliant graphically based electronic system for clinical research documentation. *Journal of Medical Systems*, **2012**, 36, 1661-72	5.1	5
32	Skin blood flow abnormalities in diabetic dermopathy. *Journal of the American Academy of Dermatology*, **2011**, 65, 559-563	4.5	12
31	Review of the safety and efficacy of linagliptin as add-on therapy to metformin in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled study. *Postgraduate Medicine*, **2011** , 123, 183-6	3.7	5
30	Insulin Glargine: a review 8 years after its introduction. *Expert Opinion on Pharmacotherapy*, **2009**, 10, 705-18	4	33
29	Alogliptin: a new addition to the class of DPP-4 inhibitors. *Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy*, **2009**, Volume 2, 117-126	3.4	29

28	Insulin: moments in history. *Drug Development Research*, **2008**, 69, 95-100	5.1	3
27	Insulin treatment of post-prandial hyperglycemia. *Drug Development Research*, **2008**, 69, 124-129	5.1	
26	Postprandial hyperglycemia: Why do we care about it? What should we do?. *Drug Development Research*, **2006**, 67, 582-586	5.1	
25	Report on the 2nd Annual Metabolic Diseases World Summit. *Expert Review of Endocrinology and Metabolism*, **2006**, 1, 467-468	4.1	
24	Targeting postprandial hyperglycemia. *Metabolism: Clinical and Experimental*, **2006**, 55, 1263-81	12.7	62
23	Manifestations of cutaneous diabetic microangiopathy. *American Journal of Clinical Dermatology*, **2005**, 6, 225-37	7.1	72
22	Skin blood flow in diabetic dermopathy. *Archives of Dermatology*, **2004**, 140, 1248-50		38
21	The role of sulphonylureas in the management of type 2 diabetes mellitus. *Drugs*, **2004**, 64, 1339-58	12.1	216
20	Cutaneous blood flow and peripheral resistance in type II diabetes as compared to intermittent claudication patients. *International Journal of Angiology*, **2003**, 12, 166-171	1.1	9
19	Combination therapy with pioglitazone plus metformin or sulfonylurea in patients with Type 2 diabetes: influence of prior antidiabetic drug regimen. *Journal of Diabetes and Its Complications*, **2003**, 17, 211-7	3.2	27
18	A comparison of the effects of rosiglitazone and glyburide on cardiovascular function and glycemic control in patients with type 2 diabetes. *Diabetes Care*, **2002**, 25, 2058-64	14.6	233
17	Skin blood flow response in the rat model of wound healing: expression of vasoactive factors. *Journal of Surgical Research*, **2002**, 107, 18-26	2.5	7
16	Cilostazol treatment of claudication in diabetic patients. *Current Medical Research and Opinion*, **2002**, 18, 479-87	2.5	14
15	Pioglitazone hydrochloride in combination with sulfonylurea therapy improves glycemic control in patients with type 2 diabetes mellitus: a randomized, placebo-controlled study. *American Journal of Medicine*, **2001**, 111, 10-7	2.4	207
14	Efficacy and safety of recombinant human nerve growth factor in patients with diabetic polyneuropathy: A randomized controlled trial. rhNGF Clinical Investigator Group. *JAMA - Journal of the American Medical Association*, **2000**, 284, 2215-21	27.4	266
13	Pioglitazone hydrochloride in combination with metformin in the treatment of type 2 diabetes mellitus: a randomized, placebo-controlled study. The Pioglitazone 027 Study Group. *Clinical Therapeutics*, **2000**, 22, 1395-409	3.5	314
12	Pharmacotherapy of type 2 diabetes mellitus. *Annals of Pharmacotherapy*, **2000**, 34, 878-95	2.9	21
11	Ischemic and pressure-induced hyperemia: a comparison. *Archives of Physical Medicine and Rehabilitation*, **1998**, 79, 1451-5	2.8	14

10	The microvascular composition of the healing wound compared at skin sites with nutritive versus arteriovenous perfusion. *Journal of Surgical Research*, **1998**, 80, 373-9	2.5	13
9	The relationship of laser-Doppler skin blood flow measurements to the cutaneous microvascular anatomy. *Microvascular Research*, **1998**, 55, 3-13	3.7	34
8	The skin blood flow response in wound healing. *Microvascular Research*, **1997**, 53, 222-34	3.7	32
7	The effect of polycythemia on skin blood flow in hypertensive rats. *Comparative Biochemistry and Physiology A, Comparative Physiology*, **1995**, 112, 355-363		4
6	Skin blood flow in the Wistar-Kyoto rat and the spontaneously hypertensive rat. *Comparative Biochemistry and Physiology A, Comparative Physiology*, **1993**, 106, 349-54		19
5	The Health Care Status of the Diabetic Population as Reflected by Physician Claims to a Major Insurer. *Archives of Internal Medicine*, **1993**, 153, 1360		13
4	Diabetic cutaneous microangiopathy. *American Journal of Medicine*, **1992**, 93, 611-8	2.4	70
3	C-peptide levels as a criterion in treatment of maturity-onset diabetes. *Journal of Clinical Endocrinology and Metabolism*, **1983**, 57, 1198-206	5.6	44
2	Endogenous Insulin Secretion Measured by C-peptide in Maturity-Onset Diabetes Controllable by Diet Alone. *Archives of Internal Medicine*, **1981**, 141, 1617		10
1	THE TIME COURSE OF THERAPEUTIC INTERVENTIONS FOR COVID-19		2